The bioavailability adjustment If nasal bioavailability is 3% (unenhanced), a researcher targeting systemic exposure equivalent to a 4mg subcutaneous dose would theoretically need approximately 133mg delivered nasally
UK dosing schedules, per BNF and NICE CKS, are as follows: Without neurological involvement: 1 mg IM three times a week for 2 weeks, then 1 mg IM every 23 months [14] [15] With neurological involvement: 1 mg IM on alternate days until no further improvement, then 1 mg IM every 2 months Patients should not self-initiate supplementation without first discussing it with their GP or prescribing clinician
Arteriosclerosis thrombosis Vasc Biol
These broad biological effects combined with their favorable stability profile position BPC157 as a highly promising therapeutic candidate for severe tissue injury, potentially offering advantages over conventional cytokine-based wound therapies
13) Addictions Various drugs of abuse (such as cocaine and methamphetamines), as well as alcohol, increase the production of reactive oxygen species